Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415727 | 0.86 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| SCHEMBL6936570 | 0.86 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| SCHEMBL27505917 | 0.86 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| SCHEMBL2080509 | 0.84 | SIGMAR1 (0.53) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| SCHEMBL1738860 | 0.84 | SIGMAR1 (0.53) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| SCHEMBL23058169 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| SCHEMBL8365481 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| SCHEMBL8101234 | 0.84 | SIGMAR1 (0.53) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| Hydrochloric Acid SCHEMBL15532545 | 0.82 | MITF (0.49) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF | |
| Hydrochloric Acid SCHEMBL15532543 | 0.82 | MITF (0.49) | SLC6A2SLC6A4SLC6A3SIGMAR1MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | CARAWAY THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| CN-118317963-A | TRPML modulators, compositions thereof, and methods of use | 卡拉韦治疗公司 | 2024-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136606-A1 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | MCOLN1, TRPM2, PKD2 | SLC6A2 1106/4885SLC6A4 677/4885SLC6A3 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.